Sign in
0JDK Stock Price, Chart, Stats & News
Iovance Biotherapeutics, Inc.
Save
Iovance Biotherapeutics, Inc. (0JDK) does not currently pay a dividend.
4.19B
Market cap
–
Current P/E
–
Forward P/E
0JDK chart
About
Health care
Sector
Biotechnology
Industry
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology firm committed to advancing and bringing to market innovative cancer immunotherapies. Its fundamental objective is to leverage and direct a patient's own immune system to identify and eradicate cancerous cells. The company currently oversees six ongoing Phase 2 clinical trials.
Similar securities
Based on sector and market capitalization
Report issue